Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECP plus low dose IL-2 for steroid refractory cGVHD
NCT03007238Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jan 2017
- Primary completion
- Oct 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in chronic graft-versus-host disease (cGVHD), sponsored by City of Hope. Started Jan 2017; status: completed.
02
Drugs
aldesleukin
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03007238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007238.